MCID: CNT005
MIFTS: 53

Central Nervous System Lymphoma malady

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases, Blood diseases

Aliases & Classifications for Central Nervous System Lymphoma

Aliases & Descriptions for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 14
Primary Central Nervous System Lymphoma 69
Primary Cns Lymphoma 12
Cns Lymphoma 69
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 35 200.5
NCIt 47 C9301

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Allograft rejection and NF-KappaB Family Pathway. The drugs Aprepitant and Fosaprepitant have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 12.6
2 intraocular lymphoma 11.3
3 lymphoma 11.1
4 symptomatic form of hemophilia a in female carriers 10.3 CDKN2A MYD88
5 angioma hereditary neurocutaneous 10.2 CDKN2A MGMT
6 ceroid lipofuscinosis, neuronal, 3 10.2 CDKN2A IL10
7 endometrial squamous cell carcinoma 10.2 CDKN2A MGMT
8 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IL10 IL2
9 tongue squamous cell carcinoma 10.2 FOXP1 MYD88
10 malignant pleural solitary fibrous tumor 10.1 CDKN2A IL2 MGMT
11 al gazali sabrinathan nair syndrome 10.1 CXCL12 CXCR4
12 plantar wart 10.1 IL10 IL2
13 louse-borne relapsing fever 10.1 CDKN2A IL2
14 meningitis 10.1
15 paramyloidosis 10.1 CXCR4 MYD88 PAX5
16 angiosarcoma 10.1 CXCR4 MYD88 PAX5
17 nonspecific interstitial pneumonia 10.0 IL10 IL2 TCN2
18 glioblastoma 10.0
19 hyperphosphatasia with mental retardation syndrome 2 10.0 CDKN2A FOXP1 PAX5
20 amblyopia 10.0 CDKN2A IL2 PAX5
21 carnitine-acylcarnitine translocase deficiency 10.0 IL2 PAX5 PRDM1
22 b-cell lymphomas 10.0
23 hepatitis 10.0
24 endotheliitis 10.0
25 encephalitis 10.0
26 glioma 10.0
27 cdkn2a-related cutaneous malignant melanoma 10.0 MTR TCN2
28 exophthalmos 10.0 CXCR4 IL10 IL2
29 granuloma inguinale 10.0 CXCL12 CXCR4 MYD88 PAX5
30 xeroderma pigmentosum, group b 9.9 CXCL12 CXCR4
31 diffuse large b-cell lymphoma 9.9
32 retinitis 9.9
33 hepatitis b 9.9
34 lymphomatous meningitis 9.9
35 acquired immunodeficiency syndrome 9.9
36 hemophagocytic lymphohistiocytosis 9.9 CXCL12 CXCR4 IL2 PAX5
37 anus leiomyosarcoma 9.9 CXCL12 CXCR4 IL10 IL2
38 adult acute lymphocytic leukemia 9.9 CDKN2A CXCR4 IL2 PAX5
39 islet cell tumor 9.9 CXCL12 CXCR4 IL10 PAX5
40 cranioectodermal dysplasia 1 9.9 CDKN2A CXCL12 CXCR4 IL2
41 myosclerosis, congenital 9.9 MTR TCN2
42 arthritis 9.8
43 neurofibromatosis 9.8
44 cerebritis 9.8
45 rheumatoid arthritis 9.8
46 hodgkin lymphoma 9.8
47 neurofibromatosis, type 1 9.8
48 richter's syndrome 9.8
49 primary tubular proximal acidosis 9.8 CDKN2A CXCL12 IL2 MGMT MYD88 PAX5
50 meningoencephalitis 9.7

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 MALT1 MYD88 CDKN2A CXCR4 IL10 IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 MALT1 MYD88 CDKN2A CXCR4 IL10 IL2

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CDKN2A CXCL12 CXCR4 IL10 IL2 MYD88
2 hematopoietic system MP:0005397 10.06 MALT1 MYD88 PAX5 PRDM1 CDKN2A CXCL12
3 immune system MP:0005387 10.02 CDKN2A CXCL12 CXCR4 IL10 IL2 MALT1
4 mortality/aging MP:0010768 10.02 CDKN2A CXCL12 CXCR4 IL10 IL2 MGMT
5 endocrine/exocrine gland MP:0005379 9.98 CDKN2A CXCR4 IL10 IL2 MGMT MYD88
6 neoplasm MP:0002006 9.86 CDKN2A CXCR4 IL10 IL2 MGMT MYD88
7 no phenotypic analysis MP:0003012 9.7 CDKN2A CXCL12 IL10 IL2 MGMT MYD88
8 reproductive system MP:0005389 9.5 CDKN2A CXCL12 CXCR4 IL10 IL2 MYD88
9 respiratory system MP:0005388 9.1 CDKN2A CXCR4 IL10 IL2 MGMT MYD88

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 537)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 170729-80-3 151165 6918365
2
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
3
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
6
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1 4291-63-8 20279
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 147-94-4 6253
9
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
15
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
17
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
18
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
19
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
20
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
21
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
22
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
23
Granisetron Approved, Investigational Phase 4,Phase 2 109889-09-0 3510
24
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
25
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 65271-80-9 4212
26
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
27
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
28
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
29
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
30
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
31
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
32
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
33
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2 137-58-6 3676
34
Nitric Oxide Approved Phase 4 10102-43-9 145068
35
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
36
Prilocaine Approved Phase 4 721-50-6 4906
37
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
38
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
41
Substance P Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 33507-63-0 44359816
42
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
43
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
44
Fotemustine Experimental Phase 4
45 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 neurokinin A Phase 4,Phase 2,Phase 1,Early Phase 1
49 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 758)
id Name Status NCT ID Phase
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4
4 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
5 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
6 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4
7 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4
8 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4
9 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4
10 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4
11 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4
12 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4
13 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
14 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4
15 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Recruiting NCT02894645 Phase 4
16 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
17 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4
18 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Recruiting NCT00846703 Phase 4
19 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Active, not recruiting NCT02576327 Phase 4
20 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4
21 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4
22 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3
23 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
24 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
25 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
26 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
27 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3
28 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Unknown status NCT00016887 Phase 3
29 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3
30 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3
31 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3
32 A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Unknown status NCT01303887 Phase 3
33 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3
34 Treatment of Acute Lymphoblastic Leukemia in Children Unknown status NCT00400946 Phase 3
35 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
36 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
37 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
38 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
39 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
40 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
41 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
42 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
43 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
44 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed NCT00005596 Phase 3
45 Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia Completed NCT00795756 Phase 2, Phase 3
46 Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET Completed NCT00583323 Phase 3
47 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
48 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
49 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3
50 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

MalaCards organs/tissues related to Central Nervous System Lymphoma:

39
Brain, B Cells, T Cells, Endothelial, Kidney, Pituitary, Spinal Cord

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

18
Central Nervous System

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 653)
id Title Authors Year
1
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( 27713090 )
2017
2
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
3
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. ( 28084866 )
2017
4
Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma. ( 27959415 )
2017
5
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. ( 28012348 )
2017
6
Trends in primary central nervous system lymphoma incidence and survival in the U.S. ( 27018254 )
2016
7
Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. ( 27375157 )
2016
8
Management of primary central nervous system lymphoma in children. ( 27913505 )
2016
9
Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. ( 27294357 )
2016
10
Central nervous system lymphoma: a morphological MRI study. ( 27857050 )
2016
11
The challenge of adequate imaging surveillance in primary central nervous system lymphoma. ( 28025387 )
2016
12
5-aminolaevulinic acid-induced fluorescence in primary central nervous system lymphoma. ( 27838426 )
2016
13
TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. ( 27101868 )
2016
14
Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient. ( 27436023 )
2016
15
Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma. ( 27543094 )
2016
16
Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study. ( 26871782 )
2016
17
Primary central nervous system lymphoma mimicking cerebellopontine angle tumour. ( 27452624 )
2016
18
Late relapse of primary central nervous system lymphoma. ( 27397141 )
2016
19
Occam's Razor Need Not Apply: A Case of Concurrent Cryptococcal Meningitis and Primary Central Nervous System Lymphoma in an Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patient. ( 26835474 )
2016
20
Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. ( 27123138 )
2016
21
Enhanced MRI and 18F-FDG PET/CT Findings of Primary Central Nervous System Lymphoma Mimicking Encephalitis. ( 27355853 )
2016
22
Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? ( 27894359 )
2016
23
Primary central nervous system lymphoma (PCNSL). ( 27191242 )
2016
24
CD4-Positive T-Cell Primary Central Nervous System Lymphoma in an HIV Positive Patient. ( 27124906 )
2016
25
Long-term survival in AIDS-related primary central nervous system lymphoma. ( 27576871 )
2016
26
Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. ( 27567676 )
2016
27
Neuroimaging in Central Nervous System Lymphoma. ( 27443998 )
2016
28
A False-Negative Case of Primary Central Nervous System Lymphoma on 11C-Methionine PET and Intense 18F-FDG Uptake. ( 27187734 )
2016
29
Application value of magnetic resonance imaging in diagnosing central nervous system lymphoma. ( 27182246 )
2016
30
Primary central nervous system lymphoma. ( 27913504 )
2016
31
mTORC1 signaling in primary central nervous system lymphoma. ( 27512609 )
2016
32
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( 26918738 )
2016
33
Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study. ( 27066340 )
2016
34
Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement. ( 27914618 )
2016
35
Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. ( 27050077 )
2016
36
The Influence of Corticosteroids on Diagnostic Accuracy of Biopsy for Primary Central Nervous System Lymphoma. ( 27468790 )
2016
37
Involvement of cranial nerves in a patient with secondary central nervous system lymphoma. ( 27208575 )
2016
38
Primary central nervous system lymphoma of T-cell origin: an unusual cause of spinal cord disease. ( 27878765 )
2016
39
Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response. ( 27390318 )
2016
40
Unusual relapse of primary central nervous system lymphoma. ( 27066337 )
2016
41
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL). ( 27752883 )
2016
42
The Challenge of Primary Central Nervous System Lymphoma. ( 27888882 )
2016
43
Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma. ( 27490760 )
2016
44
MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. ( 27161435 )
2016
45
A Case of Primary Central Nervous System Lymphoma Located at Brain Stem in a Child. ( 27867930 )
2016
46
Clinical Utility of Thallium-201 Single Photon Emission Computed Tomography and Cerebrospinal Fluid Epstein-Barr Virus Detection Using Polymerase Chain Reaction in the Diagnosis of AIDS-Related Primary Central Nervous System Lymphoma. ( 27330874 )
2016
47
MicroRNA-184 Modulates Human Central Nervous System Lymphoma Cells Growth and Invasion by Targeting iASPP. ( 28012196 )
2016
48
Demyelination as a harbinger of lymphoma: a case report and review of primary central nervous system lymphoma preceded by multifocal sentinel demyelination. ( 27206499 )
2016
49
Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis. ( 26969774 )
2016
50
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. ( 27530779 )
2016

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9 (show all 31)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 5
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 5
3 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 5
4 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 5
5 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 5
6 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 5
7 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 5
8 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 5
9 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 5
10 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 5
11 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 5
12 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 5
13 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 5
14 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 5
15 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 5
16 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 5
17 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 5
18 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 5
19 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 5
20 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 5
21 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 5
22 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 5
23 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 5
24 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 5
25 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 5
26 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 5
27 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 5
28 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 5
29 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 5
30 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 5
31 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 5

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

GO Terms for Central Nervous System Lymphoma

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to virus GO:0009615 9.58 CXCL12 CXCR4 MYD88
2 cobalamin metabolic process GO:0009235 9.46 MTR TCN2
3 negative regulation of growth of symbiont in host GO:0044130 9.43 IL10 MYD88
4 response to molecule of bacterial origin GO:0002237 9.37 IL10 MALT1
5 negative regulation of apoptotic process GO:0043066 9.35 IL10 IL2 MALT1 MGMT MYD88
6 positive regulation of interleukin-17 production GO:0032740 9.32 IL2 MYD88
7 negative regulation of B cell apoptotic process GO:0002903 9.26 FOXP1 IL2
8 regulation of tumor necrosis factor production GO:0032680 9.16 FOXP1 MYD88
9 negative regulation of B cell proliferation GO:0030889 8.8 CDKN2A IL10 PRDM1

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 methyltransferase activity GO:0008168 9.5 MGMT MTR PRDM1
2 growth factor activity GO:0008083 9.43 CXCL12 IL10 IL2
3 cobalamin binding GO:0031419 9.16 MTR TCN2
4 kinase activator activity GO:0019209 8.96 IL2 MALT1
5 protein self-association GO:0043621 8.8 FOXP1 MALT1 MYD88

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....